Clinical trials: Progressive IgA Nephropathy
Primary IgA Nephropathy
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal…
- Trial name
- Nefigard (NCT03643965)
- Testing
- Nefecon
- Where
- 142 sites in United States, Argentina and 17 more
- Volunteers
- 365 people
- Sponsor
- Calliditas Therapeutics AB
IgA Nephropathy, Immunoglobulin A Nephropathy
Atrasentan in Patients With IgA Nephropathy
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
- Trial name
- ALIGN (NCT04573478)
- Testing
- Atrasentan, Zigakibart
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
Progressive IgA Nephropathy, Proteinuria
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in…
- Trial name
- NCT02282930
- Testing
- ACTH (Acthar) Gel
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
IgA Nephropathy
Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive supportive therapy to induce a clinical remission in patients at risk for progressive IgAN Investigation of differences between the treatments…
- Trial name
- STOP-IgAN (NCT00554502)
- Testing
- supportive therapy with: ACE-inhibitor / ARB / Statin, supportive and immunosuppressive therapy
- Where
- 34 sites in Germany
- Volunteers
- 148 people
- Sponsor
- RWTH Aachen University
Glomerulonephritis, IGA, Kidney Diseases
Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
Crescentic IgA nephropathy (CreIgAN) has a poor prognosis despite aggressive immunosuppressive therapy. The efficacy of plasma exchange (PE) in CreIgAN is not well defined.
- Conditions
- Glomerulonephritis, IGA, Kidney Diseases, Acute Renal Insufficiency, Rapidly Progressive Glomerulonephritis
- Trial name
- RESCUE (NCT02647255)
- Testing
- Plasma Exchange (PE), Methylprednisolone pulse
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Peking University First Hospital
Glomerulonephritis, IGA, Renal Insufficiency, Chronic
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
IgA nephropathy is the most common primary glomerulonephritis in the world. Because of the poor treatment effect in advanced patients, it is still the main cause of maintenance dialysis.
- Trial name
- NCT04020328
- Testing
- Leflunomide 20 mg+prednisone 0.5mg/kg/d
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shenzhen Second People's Hospital
IgA Nephropathy
Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
This study was about IgA nephropathy, a form of kidney disease characterized by the presence of blood and protein in the urine. This study was done to determine if the medication rituximab could reduce protein in the patient's…
- Trial name
- NCT00498368
- Testing
- Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Cancer
Wormwood in Chronic Progressive Disorders With Reduced Appetite
Wormwood is approved herbal medicine for the treatment of reduced appetite in Germany (Registration No.: 1339.99.99). Reduced appetite is observed in many chronic health disorders such as old age, immune disorders and cancer.
- Trial name
- NCT01126931
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital Freiburg
IgA Nephropathy
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
The anti-hinge region antibodies would be a relevant biomarker of IgA nephropathy. Beyond a prognostic value (which could increase the risk of Renal Absolute), the longitudinal monitoring for these antibodies could be of…
- Trial name
- NIGA-RA (NCT02526966)
- Testing
- blood sample
- Where
- 15 sites in France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne